Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iclaprim vs Vancomycin in ABSSSI (REVIVE-2)
NCT02607618Phase 3Completed
- Sponsor
- Motif Bio plc
- Start
- Nov 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of Iclaprim in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Motif Bio plc. Started Nov 2015; status: completed.
02
Drugs
Iclaprim
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02607618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607618.